Louis Dubeau, MD, PhD

Keck School of Medicine, University Southern California, Los Angeles, CA, USA

Dr. Dubeau received his medical training at McGill University in Montreal (Canada), where he completed a residency in anatomic pathology. Dr. Dubeau also received a Ph.D. in Biochemistry from the same institution. He is a surgical pathologist certified by the American Board of Pathology and currently Medical Director of Molecular Pathology at the University of Southern California. Dr. Dubeau’s research program focuses on the biology and molecular genetics of ovarian cancer. Early in his career he became intrigued by the prevailing idea at the time that these tumors originate from the thin tissue layer that line the ovarian surface. Dr. Dubeau gradually became convinced that this was not their true site of origin and published several papers on this subject. Although initially regarded as highly provocative, these ideas have subsequently become accepted by the scientific community based on observations on the location of early cancers in individuals carrying predisposing germline mutations such as BRCA1 mutation carriers. Dr. Dubeau continues to address issues about the site of histogenesis of these tumors, which is relevant to efforts toward early ovarian cancer detection, using appropriate mouse models developed in his laboratory. Another important focus of his research is on the understanding of the mechanisms underlying the risk factors for these tumors and, specifically, how genetic factors such as germline BRCA1 mutations interact with hormonal factors associated with the menstrual cycle to increase cancer risk. Dr. Dubeau developed mouse models and collaborated in human population-based studies supporting the idea that such interaction does play an important role in cancer predisposition in BRCA1 mutation carriers and he is currently focused on developing means of cancer risk reduction by interfering with such interactions. Given Dr. Dubeau’s position as Medical Director of Molecular Pathology, a significant proportion of his effort also goes toward the development of molecular tests relevant to cancer diagnosis and management.

Terms of Appointment: Jun 2018 - May 2020